Stride, a Norwich-based preventative health startup founded by former Team GB sprinter Andrew Steele, has raised £4.6 million in a seed round. The company takes its total funding to nearly £5 million and is using the money to build out its platform and launch its membership in the United States before the end of 2026.

The round was backed by Arāya Ventures, Morgan Stanley Inclusive & Sustainable Ventures, Better Ventures, Innovate UK, an investor from the a16z Scout Fund, and a group of angel investors.

What Stride does

Stride sells a diagnostics-driven health membership, launched in May 2024, that it calls one of the UK's first of its kind. Instead of waiting for symptoms, the idea is to test people while they are well and track how their health moves over time.

A membership combines three types of testing. DNA tests look at genetic markers, blood tests measure biomarkers, and gut tests profile the microbiome. Members get personalised insights from those results, can book consultations with a dietitian, and can order supplements through the platform. Test kits ship from a UK laboratory to customers worldwide.

Its newer tier, Stride One, estimates a person's biological age from nine blood biomarkers. Biological age tries to measure how worn the body actually is, which can differ from the number on a birth certificate. That is the product heading to the US first.

You can see the full membership on the company's official site. The one metric Stride has disclosed is retention: it says it has kept 85 per cent of customers over its first 13 months, which is high for a consumer health subscription and the main reason investors took the round seriously.

The founder: an Olympic medal that arrived nine years late

Andrew Steele ran the 400m and 4x400m relay for Great Britain for 13 years. At the 2008 Beijing Olympics his relay team finished fourth. Nine years later, after stored samples from another team were retested and that team was disqualified, the British quartet was awarded bronze. Steele has been open about how the near-miss shaped him, telling City AM that the long wait for the medal "forced me to face the rest of my life four or eight years sooner than I had expected."

He went on to co-found the genetic testing company DNAfit, which Prenetics bought in 2018 for a reported $10 million. Prenetics later listed on the Nasdaq in 2022 at a valuation above $1 billion. Steele stayed on as a product lead for the EMEA region before leaving to build Stride.

His pitch leans on his own career. As an elite athlete he had a nutritionist, a strength coach, a psychologist and a physio reading his data and adjusting what he did every day. Stride is an attempt to package that feedback loop for people who are not professional athletes. Steele argues the wearables market shows the appetite is there. "There's pretty widespread adoption of a £1,000 device in the iPhone," he told City AM. "This can be absolutely the same level."

Steele is blunt that the category has an image problem. "Preventative health can sometimes sound boring or worthy, when actually it could be one of the most transformative opportunities of our generation," he said. He makes a provocative claim to back it: preventing a range of diseases through everyday behaviour change could add more years to the average life than eradicating cancer entirely would.

Where the money goes

Two parts of the plan stand out. The first is the US launch of Stride One, which is where most consumer longevity spending is happening and where rivals have raised far larger sums. The second is research. Innovate UK is funding two projects: a multiomic method for measuring biological age, which combines several biological signals rather than relying on one, and an AI "health copilot" that would pull together lab results, wearable data and health records into a single view.

Stride is also building distribution through hospitality rather than clinics. It runs a health concierge with Triple Bond at The BoTree hotel in Marylebone and works with LongLane, an alcohol-free wellness club near Midhurst in West Sussex, using its testing to personalise what members get. Rupa Popat, founder and managing partner at Arāya Ventures, said Stride "sits at the intersection of some of the most important shifts in healthcare."

A crowded and well-funded field

Preventative and longevity health is one of the busier corners of consumer healthtech, and Stride is a small raise in it. In the UK, Zoe built a large business around gut-health testing and personalised nutrition, and Thriva pioneered at-home blood testing by subscription. In the US, where Stride is heading, Function Health and Superpower have each raised tens of millions of dollars selling annual blood-panel memberships, and Neko Health, co-founded by Spotify's Daniel Ek, raised $260 million in 2026 for its body-scanning clinics. Against those numbers, £4.6 million buys focus, not a land grab.

That gap is the risk and the point. The bigger players are spending heavily to win the same customer, and a UK startup entering the US with a single membership tier will have to show its testing and retention travel. Stride's answer is that 85 per cent retention figure and a founder who has sold a genetics company before. Whether that is enough to hold margins once US customer-acquisition costs hit is the open question, and it is the one the next round will be judged on.

The wider backdrop helps. The UK had its strongest first half for startup funding since 2022 earlier this year, and healthtech has been a reliable draw even as other sectors cooled. Bizztor's look at how the UK held second place globally for tech funding in 2025 sets out why overseas capital keeps finding British health companies, and smaller rounds such as UK healthtech startup Nul's £1 million seed show the early-stage pipeline behind the headline deals. For founders in the space, the read-through from Shemed's £43 million raise is that consumer health businesses with real retention can still command serious capital in a cautious market.

For now, Stride has enough to make its US move and prove the model in a market that rewards it. The harder test, turning a wait-and-see product into something people buy as readily as a phone, is still ahead.